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Background: The P2X7 receptor is a member of the P2X family of adenosine 5′-triphosphate-gated cation channels.
Several recent studies have demonstrated that this receptor is involved in mechanisms related to pain and inflammation.
However, unknown is whether polymorphisms of the P2RX7 gene that encodes the human P2X7 receptor influence pain
sensitivity and analgesic effects of opioids. The P2RX7 gene is known to be highly polymorphic. Thus, the present study
examined associations between fentanyl sensitivity and polymorphisms in the P2RX7 gene in 355 Japanese patients who
underwent painful orofacial cosmetic surgery.
Results: We first conducted linkage disequilibrium (LD) analyses for 55 reported single-nucleotide polymorphisms (SNPs)
in the region within and around the P2RX7 gene using genomic samples from 100 patients. In our samples, 42 SNPs were
polymorphic, and a total of five LD blocks with six Tag SNPs (rs2708092, rs1180012, rs1718125, rs208293, rs1718136, and
rs7132846) were observed. Thus, we further analyzed associations between genotypes/haplotypes of these Tag
SNPs and clinical data using a total of 355 samples. In the genotype-based association study, only the rs1718125
G > A SNP tended to be associated with higher pain scores on a visual analog scale 24 h after surgery (VAS24). The
haplotype-based association study showed that subjects with homozygous haplotype No.3 (GTAAAC; estimated
frequency: 15.0%) exhibited significantly higher cold pain sensitivity and lower analgesic effects of fentanyl for acute
cold pain in the cold pressor test. Conversely, subjects who carried haplotype No.1 (ACGGAC; estimated frequency:
24.5%) tended to exhibit lower cold pain sensitivity and higher analgesic effects of fentanyl. Furthermore, subjects with
homozygous haplotype No.2 (GCGGAC; estimated frequency: 22.9%) exhibited significantly lower VAS24 scores.
Conclusions: Cold pain sensitivity and analgesic effects of fentanyl were related to the SNP and haplotypes of
the P2RX7 gene. The patients with the rs1718125 G>A SNP tended to show higher VAS24 scores. Moreover, the
combination of polymorphisms from the 5′-flanking region to exon 5 recessively affected cold pain sensitivity and
analgesic effects of opioids for acute cold pain. The present findings shed light on the involvement of P2RX7 gene
polymorphisms in naive cold pain sensitivity and analgesic effects of fentanyl.
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Extracellular adenosine 5′-triphosphate (ATP) has been
recognized as a neurotransmitter and/or neuromodu-
later in the nervous system that specifically acts on P2
purinergic receptors on the cell surface. P2 purinergic
receptors are divided into two classes. P2X receptors
are ATP-gated cation channels and subdivided into
seven subtypes (P2X1–7). P2Y receptors are heptahelical
G-protein-coupled receptors and subdivided into eight
subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13,
and P2Y14). Both P2X and P2Y receptors are widely
expressed in the sensory nerve system and exert various
effects on neuronal and glial cells [1]. Recent studies
revealed that ATP and its receptors are involved in
peripheral and central nociceptive transmission, includ-
ing mechanisms involved in neuropathic pain [2,3].
P2X7 receptors exhibit unique pharmacological char-
acteristics compared with other P2X receptor subtypes.
A high concentration of ATP (i.e., >100 μM) is required
for P2X7 receptor activation [4]. In addition to acting as
ATP-gated Ca2+-permeable cation channels, P2X7 recep-
tors induce the formation of large nonselective pores
with a 900 Da cut-off [4,5]. Many studies have shown
the involvement of P2X7 receptors in pain. P2X7 recep-
tor knockout mice have been shown to exhibit a reduc-
tion of thermal and mechanical hypersensitivity in a
partial sciatic nerve ligation model [6]. Recent develop-
ments in selective inhibitors of P2X7 receptors also
showed that P2X7 receptor blockade reduced nociceptive
behavior in several animal models of neuropathic and in-
flammatory pain [7-10]. Although these studies revealed
an important role for P2X7 receptors in neuropathic and
inflammatory pain development in animal models, the
involvement of P2X7 receptors in the modulation of
naive pain sensitivity and efficacy of analgesics in humans
is still unclear.
Opioid analgesics, such as fentanyl and morphine, are
widely used for the treatment of moderate to severe
pain. However, the analgesic efficacy of opioids is well
known to vary widely among individuals [11]. Individual
differences may be related to various genetic and nonge-
netic factors, including gender, age, ethnic origin, hepatic
or renal function, and mental status [12]. Several studies
that used mice that lack the μ-opioid receptor (MOP)
[13-15] have shown that analgesia produced by opioids
crucially depends on the level of MOP expression. Fur-
thermore, several single-nucleotide polymorphisms (SNPs)
in the OPRM1 gene, which encodes the human MOP pro-
tein, have been reported to lead to differences in the anal-
gesic efficacy of opioids [16]. Several gene-association
studies have also reported that the analgesic efficacy of
opioids could be affected by other molecules [17-21].
Many gene polymorphisms, most of which are SNPs,
reportedly exist in the genes that encode P2X and P2Yreceptors. The gene that encodes the human P2X7
receptor (P2RX7) is known to be highly polymorphic.
Some SNPs in the P2RX7 gene have been shown to
cause changes in receptor function [22-24]. Only a few
studies have tested associations with human pain sensi-
tivity [24], and whether genetic polymorphisms in the
P2RX7 gene exhibit associations with pain sensitivity or
opioid analgesia is still unclear. In contrast to animal
studies that use standardized pain tests, the analgesic
effects of opioids in humans are usually evaluated in
patients with actual pain, particularly cancer pain or
acute postoperative pain [16]. Patients with acute post-
operative pain following standardized surgical proce-
dures may be more optimal subjects for investigating
gene-opioid effect relationships [11,17,25]. Further-
more, because subjects prior to cosmetic orthognathic
surgery have no spontaneous pain, the analgesic effects
of opioids in humans can be evaluated under more opti-
mal conditions. Therefore, the present study examined
whether SNPs and haplotypes in the P2RX7 gene affect
cold pain sensitivity and the analgesic effects of fentanyl,
one of the most commonly used opioid analgesics, evalu-
ated by a standardized pain test and fentanyl requirements




The study protocol was approved by the Institutional
Review Board, Tokyo Dental College, Chiba, Japan, and
the Institutional Review Board, Tokyo Metropolitan
Institute of Medical Science, Tokyo, Japan. Written in-
formed consent was obtained from all of the patients and
also from parents if required.
Patients
Enrolled in the study were 355 healthy patients (American
Society of Anesthesiologists Physical Status I, age 15–52
years, 125 males and 230 females [the same patients who
served as subjects in our previous report] [17]) who were
scheduled to undergo cosmetic orthognathic surgery
(mandibular sagittal split ramus osteotomy) for mandibu-
lar prognathism at Tokyo Dental College Suidoubashi
Hospital. Patients with chronic pain, those taking pain
medication, and those who had experienced Raynaud’s
phenomenon were excluded.
Preoperative cold pressor-induced pain test
The patients were premedicated with oral diazepam,
5 mg, and oral famotidine, 150 mg, 90 min before the
induction of anesthesia. The patients had an intravenous
(i.v.) line on the forearm on their nondominant side.
The temperature in the operating room was maintained
at 26°C. The cold pressor-induced pain test was then
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of fentanyl, 2 μg/kg, as previously described [25,26].
Briefly, crushed ice cubes and cold water were blended
15 min before the test in a 1 L isolated tank, and the
mixture was stirred immediately before each test to
ensure uniform temperature distribution (0°C) within
the tank. The dominant hand was immersed up to the
wrist. Patients were instructed to keep the hand calm in
the ice-cold water and withdraw it as soon as they per-
ceived any pain. All of the patients were administered
the test by the same investigator. The baseline latency
to pain perception, defined as the time of immersion of
the hand in the ice water, before an i.v. injection of
fentanyl (PPLpre) was recorded. A cut-off point of 150 s
was set to avoid tissue damage. The hand was warmed
with a hair dryer as soon as it was withdrawn from the
ice water until the sensation of cold was completely
abolished. The patients then received i.v. fentanyl, 2 μg/kg.
Three minutes after the injection, the pain perception
latency of the dominant hand (PPLpost) was measured
again. The analgesic effect of fentanyl in the preoperative
cold pressor-induced pain test was evaluated simply as
the difference between PPLpost and PPLpre (PPLpost -
PPLpre).
Anesthesia, surgery, and postoperative pain management
Anesthesia, surgery, and postoperative pain management
were performed as previously described [17]. Briefly, after
the cold pressor-induced pain test ended, general anesthesia
was induced with a target-controlled infusion (TCI) of
propofol. After the induction of anesthesia, 10 ml of
venous blood was sampled for the preparation of DNA
specimens. Local anesthesia was performed on the right
side of the surgical field with 8 ml of 2% lidocaine that
contained epinephrine, 12.5 μg/ml, and right mandibu-
lar ramus osteotomy was performed. Local anesthesia
was then performed on the left side, and left mandibular
ramus osteotomy was performed. The bilateral man-
dibular bone segments were fixed in appropriate posi-
tions. Whenever systolic blood pressure or heart rate
exceeded +20% of the preinduction value during sur-
gery, i.v. fentanyl, 1 μg/kg, was administered. At the end
of the surgery, rectal diclofenac sodium, 50 mg, and i.v.
dexamethasone, 8 mg, were administered at the request
of surgeons to prevent postoperative orofacial edema/
swelling. After emergence from anesthesia and tracheal
extubation, i.v. patient-controlled analgesia (PCA) with
a fentanyl-droperidol combination (2 mg fentanyl and
5 mg droperidol diluted in normal saline in a total
volume of 50 ml) commenced using a CADD-Legacy
PCA pump (Smiths Medical Japan, Tokyo, Japan). A
bolus dose of fentanyl, 20 μg, on demand and a lockout
time of 10 min were set. Patient-controlled analgesia
continued for 24 h postoperatively. The intensity ofspontaneous pain was assessed 3 and 24 h postoperatively
using a 100-mm visual analog scale (VAS), with 0 mm
indicating no pain and 100 mm indicating the worst
pain imaginable. Intraoperative fentanyl use and post-
operative PCA fentanyl use during the first 24 h postopera-
tive period were recorded. Doses of fentanyl administered
intraoperatively and postoperatively were normalized to
body weight. Additionally, perioperative fentanyl use was
calculated as the sum of intraoperative fentanyl use and
postoperative fentanyl use.
Genotyping procedures and linkage disequilibrium
analysis
Genomic DNA was extracted from whole-blood samples
using standard procedures. The extracted DNA was dis-
solved in TE buffer (10 mM Tris–HCl, 1 mM ethylenedi-
aminetetraacetic acid, pH 8.0). The DNA concentration
was adjusted to 5–50 ng/μl for genotyping individual SNPs
or 100 ng/μl for whole-genome genotyping using a Nano-
Drop ND-1000 Spectrophotometer (NanoDrop Technolo-
gies, Wilmington, DE, USA).
For the analysis of SNPs within and around the P2RX7
gene region, genotype data from whole-genome genotyp-
ing were used. Briefly, whole-genome genotyping was
performed using Infinium assay II and an iScan system
(Illumina, San Diego, CA) according to the manufacturer’s
instructions. Five kinds of BeadChips were used to genotype
40, 67, 6, 119, and 123 samples, respectively: HumanHap
300 (total markers: 317,503), HumanHap300-Duo (total
markers: 318,237), Human610-Quad v1 (total markers:
620,901), Human1M v1.0 (total markers: 1,072,820), and
Human 1 M-Duo v3 (total markers: 1,199,187). Some Bead-
Chips included a number of probes specific to copy number
variation markers, but most were for SNP markers on
the human autosome or sex chromosome. Approxi-
mately 300,000 SNP markers were commonly included
in all of the BeadChips. After the whole-genome geno-
typing, the data for genotyped samples were analyzed
using BeadStudio or GenomeStudio with the Genotyp-
ing module v3.3.7 (Illumina) to evaluate the quality of
the results, and the genotype data for all of the SNPs with
P2RX7 gene annotation were extracted. In the data-
cleaning process, markers that had “Cluster sep” values
(i.e., an index of genotype cluster separation) <0.4 and
were separated from any of the three genotype clusters
were excluded from the subsequent association study.
Single-nucleotide polymorphisms for the association
studies were selected based on recently advanced tagging
strategies [27-29]. To identify relationships between the
SNPs used in the study, linkage disequilibrium (LD)
analysis was performed in 55 SNPs that were in the
approximately 108 kbp region that contained the P2RX7
gene among 1,072,820 markers in the Human 1 M v1.0
BeadChip for 100 samples using Haploview v.4.2 [30].
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the commonly used D’ and r2 values were pairwise
calculated using the genotype dataset of each SNP.
Linkage disequilibrium blocks were defined among the
SNPs that showed “strong LD,” based on the default al-
gorithm of Gabriel et al. [31], in which the upper and
lower 95% confidence limits on D’ for strong LD were set
at 0.98 and 0.7, respectively. Tag SNPs in the LD block
were consequently determined using Tagger software with
default settings, which is incorporated in Haploview and
has been detailed in a previous report [29].
Statistical analysis
Parametric and nonparametric data are expressed as
mean ± SD and median [interquartile range], respectively.
The statistical analysis was performed using IBM SPSS
statistics v.20.0.0 (IBM, Tokyo, Japan). In the present
study, none of the clinically measured endpoints that were
related to pain sensitivity (i.e., PPLpre) or fentanyl anal-
gesia (i.e., analgesia measured with the preoperative cold
pressor test, perioperative fentanyl use, and VAS scores at
3 and 24 h postoperatively) were normally distributed.
Therefore, nonparametric analyses, including the Mann–
Whitney U-test or Kruskal-Wallis test (with Steel-Dwass
multiple comparison tests), were used to detect possible
associations between any of the clinical or genomic pa-
rameters (e.g., sex and genotypes of the Tag SNP) and clin-
ical endpoints related to pain sensitivity or the analgesic
effects of fentanyl. The sample size of the present non-
parametric data was higher than the estimated size that
possesses statistical power (1 minus type II error probabil-
ity) of 99% for the Cohen’s conventional “medium” effect
size of 0.25, when power analysis was performed for
analysis of variance with three genotype groups using
G*Power v.3.1.3 [32]. Haplotype analyses were per-
formed using HPlus v.3.2 software with default settings
(Fred Hutchinson Cancer Research Center, Seattle, WA,
USA) that employs expectation-maximization with a
modified progressive ligation computational algorithm
to infer haplotypes [33].
Results
To identify the LD blocks in the approximately 108 kbp
region that contains the P2RX7 gene, 55 SNPs among
1,072,820 markers that were included in the whole-
genome genotyping (Human 1 M v1.0 BeadChip) were
tested using genomic samples of 100 patients who were
randomly selected from all 355 Japanese patients. In
these Japanese samples, 42 SNPs were found to be
polymorphic. A total of five LD blocks (LD1-5) were
observed within and around the P2RX7 gene region
(the exon, intron, and approximately 45 kbp 5′-flank-
ing region and 10 kbp 3′-flanking region of the P2RX7
gene [approximately 53 kbp]), and six representativeTag SNPs (rs2708092, rs1180012, rs1718125, rs208293,
rs1718136, and rs7132846) were selected in this region
(Table 1, Additional file 1). Thus, we further examined
associations between clinical endpoints and these six
representative Tag SNPs using genomic samples from
all 355 Japanese patients.
Of the 355 Japanese patients who enrolled in the
study, 353 completed the study. The distributions of six
representative Tag SNP genotypes are shown in Table 2.
No observed genotype frequencies were significantly dif-
ferent from Hardy-Weinberg equilibrium.
The Mann–Whitney U-test revealed that the VAS
score at 24 h was significantly lower (p = 0.019; Table 3)
in subjects who did not carry the minor A allele of the
rs1718125 SNP than subjects who carried this allele,
whereas the rs1718125 SNP had no significant associ-
ation with PPLpre, PPLpost-PPLpre, 24-h postoperative
fentanyl use, perioperative fentanyl use, total peri-
operative analgesic use, and the VAS score at 3 h. The
unpaired t-test, Fisher’s exact test, and Mann–Whitney
U-test revealed no significant differences in age, sex,
duration of surgery, and duration of anesthesia be-
tween subjects who carried the minor A allele and sub-
jects who did not carry this allele (p =0.079 [age:
Table 3], p = 0.740 [sex: Table 3], p =0.430 [duration of
surgery: AA + AG, 106 min (93, 128); GG, 105 min (92,
122)], and p = 0.384 [duration of anesthesia: AA + AG,
173 min (160, 195); GG, 173 min (157, 193)], respect-
ively). Therefore, we did not conduct additional multi-
variate covariate analyses. The other five SNPs did not
show any associations with any of the clinical endpoints
(Table 3). When multiple-testing corrections (i.e., the
standard Bonferroni correction for the number of SNPs)
were applied, no significant association was found be-
tween the genotype of the rs1718125 SNP and VAS
score at 24 h.
We further analyzed the haplotype-based associations
of the six P2RX7 gene Tag SNPs with clinical endpoints.
Of the 26 estimated haplotypes, 10 haplotypes (esti-
mated frequency >1%) are listed in Table 4. Haplotype
No.1 (ACGGAC) was significantly associated with both
higher PPLpre score and higher PPLpost-PPLpre score
in the linear regression analysis that used the recessive
model (Table 5) and log-additive model (PPLpre: coef-
ficient = 4.532 [confidence interval (CI): 0.048, 9.017],
z-score = 1.981, p =0.048; PPLpost-PPLpre: coefficient =
8.735 [CI: 1.829, 15.640], z-score = 2.479, p = 0.013) and
associated with higher PPLpost-PPLpre score using the
dominant model (coefficient =8.802 [CI: 0.601, 17.004],
z-score = 2.104, p = 0.035), although the adjusted
p values of these associations with haplotype No.1 after
multiple-testing corrections (i.e., the standard Bonferroni
correction for the number of clinical endpoints) were
not significant. The linear regression analyses that used
Table 1 Allelic frequencies of SNPs in five LD blocks around the P2RX7 gene of Japanese subjects
rs number of SNPs Position Major allele Minor allele Frequency LD block
rs12819523 Flanking_5UTR −45261 G A 7.5%
rs12819930 Flanking_5UTR −45087 G A 10.7% 1
rs10492051 Flanking_5UTR −45012 G - 0.0%
*rs2708092 Flanking_5UTR −44792 A G 49.0% 1
*rs1180012 Flanking_5UTR −40230 C T 38.8% 1
rs2516210 Flanking_5UTR −35256 T C 15.9% 1
rs1796421 Flanking_5UTR −30332 T C 15.9% 1
rs1796412 Flanking_5UTR −28966 T C 18.2% 1
rs7298521 Flanking_5UTR −28847 C T 22.9% 1
rs1794899 Flanking_5UTR −27705 G A 18.0% 1
rs1796415 Flanking_5UTR −27667 T - 0.0%
rs3892756 Flanking_5UTR −16010 T - 0.0%
rs10849846 Flanking_5UTR −12255 T C 21.8% 1
rs208277 Flanking_5UTR −10097 A G 41.1% 1
rs12314721 Flanking_5UTR −4921 C T 14.9% 1
rs9805004 Flanking_5UTR −4808 C T 18.2% 1
rs670541 Flanking_5UTR −1044 C T 8.9% 1
rs591874 Intron1 IVS1 + 567 A C 40.9% 1
rs7959194 Intron1 IVS1 + 5089 G - 0.0%
rs11065450 Intron1 IVS1 + 8759 C A 28.7%
rs568531 Intron1 IVS1 + 8775 C T 7.5% 2
rs607094 Intron1 IVS1 + 9566 T C 6.4% 2
rs208286 Intron1 IVS1-5688 G - 0.0%
rs17525809 Exon2 T227C[V76A] T C 8.9%
*rs1718125 Intron2 IVS2 + 263 G A 28.3% 3
rs10849851 Intron3 IVS3-2061 A G 21.0% 3
rs1653583 Intron3 IVS3-53 C T 7.2% 3
*rs208293 Intron4 IVS4-47 G A 41.1% 3
rs208294 Exon5 T463C[Y155H] T C 43.5% 3
rs1186055 Intron5 IVS5 + 206 G T 39.5%
rs208296 Intron5 IVS5 + 630 C T 36.1%
rs11065464 Intron5 IVS5-1025 C A 24.3%
rs208298 Intron5 IVS5-922 G A 16.6% 4
rs654856 Intron5 IVS5-38 C A 13.4% 4
rs2857589 Intron7 IVS7 + 486 C A 5.1% 4
rs503720 Intron7 IVS7-217 G A 16.1% 4
rs16950860 Exon8 C808T[R270C] C - 0.0%
rs7958311 Exon8 G809A[R270H] G A 35.6%
rs7958316 Exon8 G827A[R276H] G - 0.0%
*rs1718136 Intron8 IVS8-3583 A G 15.0% 5
rs7137542 Intron8 IVS8-545 G - 0.0%
*rs7132846 Intron9 IVS9-16 C T 12.9% 5
rs1718119 Exon11 G1040A[A348T] G A 17.5% 5
Ide et al. Molecular Pain 2014, 10:75 Page 5 of 11
http://www.molecularpain.com/content/10/1/75
Table 1 Allelic frequencies of SNPs in five LD blocks around the P2RX7 gene of Japanese subjects (Continued)
rs1653598 Intron11 IVS11 + 34 A G 14.9% 5
rs2567998 Intron11 IVS11-16 A - 0.0%
rs10160951 Exon12 C1289G[P430R] C - 0.0%
rs12829218 Intron12 IVS12 + 133 A - 0.0%
rs891781 Intron12 IVS12 + 180 C T 17.5% 5
rs7312642 Intron12 IVS12-1921 G T 12.1%
rs12815078 Intron12 IVS12-101 A G 6.1%
rs2230912 Exon13 A1379G[Q460R] A - 0.0%
rs3751144 Exon13 C1422T C T 12.9%
rs3751143 Exon13 A1487C[E496A] A C 32.0%
rs1718161 Flanking_3UTR +3582 A G 6.5%
rs2686365 Flanking_3UTR +9907 C - 0.0%
*Tag SNPs in the LD blocks (selected using Tagger software with default settings; r2 > 0.8).
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(GTAAAC) was significantly associated with both lower
PPLpre score and lower PPLpost-PPLpre score, even
after multiple-testing corrections (Table 5). These sig-
nificant associations were not evident when analyzed
using either a dominant or log-additive model. Further-
more, linear regression analyses that used the recessive
model also revealed that haplotype No.2 (GCGGAC)
was significantly associated with lower VAS scores at
24 h, even after multiple-testing corrections (Table 5).
This significant association was also not evident when
analyzed using either the dominant or log-additive
model.
Discussion
We studied patients who underwent mandibular sagittal
split ramus osteotomy. Subjects who undergo this cos-
metic surgery are usually young and healthy. The oper-
ation causes considerable perioperative pain that arises
from the dissected mandibular bone, and the surgical
technique is highly standardized at our institute. We
conducted a standardized pain test before the induction
of general anesthesia in opioid-naive subjects without
pain. Using these ideal subjects and methods, we found
that PPLpre and the analgesic effects of fentanyl
(PPLpost-PPLpre) evaluated in the cold pressor test were
significantly lower in subjects who carried homozygousTable 2 Distribution of six Tag SNP genotypes examined in th
rs2708092 AA: 99 (28.0%) / AG:
rs1180012 CC: 128 (36.1%) / CT:
rs1718125 GG: 180 (50.7%) / GA:
rs208293 GG: 111 (31.3%) / GA:
rs1718136 AA: 247 (69.6%) / AG:
rs7132846 CC: 274 (77.2%) / CT:
The data are expressed as number (%) of subjects.haplotype No.3 (GTAAAC) in the P2RX7 gene com-
pared with the other subjects. Subjects who carried
haplotype No.1 (ACGGAC), which has a different allele
in the Tag SNP on the LD1-3 regions from haplotype
No.3, tended to have higher PPLpre scores and higher
analgesic effects of fentanyl. These results suggest that
the combination of polymorphisms from the 5′-flanking
region to exon 5 (from LD1 to LD3 regions) in the
P2RX7 gene could recessively affect cold pain sensitivity
and the analgesic effects of opioids for acute cold pain.
Furthermore, VAS scores at 24 h tended to be lower in
subjects who carried homozygously the major G allele of
the rs1718125 SNP (3rd Tag SNP) than subjects who
carried the minor A allele. We also found that VAS
scores at 24 h were significantly lower in subjects who
carried homozygous haplotype No.2 (GCGGAC) in the
P2RX7 gene compared with the other subjects. Thus,
haplotype No.2 could recessively affect the postoperative
analgesic effects of opioids. Although we analyzed five
types of BeadChips that were merged together in the
present study because the sample sizes were small for
each of the five datasets and they all presumably had
Japanese ancestry, performing a meta-analysis is usually
better than merging. Thus, further studies that have a
greater number of samples might be required to reveal
the influences of these haplotypic effects in the P2RX7
gene. Twenty-four hour postoperative fentanyl use,e P2RX7 gene
177 (50.0%) / GG: 79 (22.0%)
169 (47.6%) / TT: 58 (16.3%)
149 (42.0%) / AA: 26 (7.3%)
177 (49.9%) / AA: 67 (18.9%)
97 (27.3%) / GG: 11 (3.1%)
75 (21.1%) / TT: 6 (1.7%)
Table 3 Patients’ demographic and clinical data
rs2708092 rs1180012 rs1718125
AA AG + GG CC CT + TT GG GA + AA
Age (years) 26.1 ± 7.0 25.8 ± 7.8 27.3 ± 7.7 25.1 ± 7.5 26.6 ± 7.7 25.2 ± 7.5
Male/Female 32/67 92/163 51/77 74/153 65/115 60/115
PPLpre (s) 15 [10,21] 14 [9,23] 14 [9,23] 14 [9, 23] 14 [9, 22] 15 [9, 23]
PPLpost (s) 29 [18, 52] 27 [16, 54] 28 [16, 49] 28 [16, 54] 27 [16, 49] 30 [16, 56]
Analgesic effect (PPLpost-PPLpre) (s) 15 [5, 35] 11 [4, 35] 10 [4, 30] 13 [4, 36] 10 [4, 30] 14 [5, 37]
24-h postoperative fentanyl use (μg/kg) 2.2 [1.2, 4.7] 2.3 [1.0, 4.1] 2.3 [0.9, 4.1] 2.3 [1.1, 4.3] 2.1 [0.9, 3.9] 2.4 [1.3, 4.4]
Perioperative fentanyl use (μg/kg) 7.6 [5.8, 9.2] 6.7 [5.1, 9.1] 6.8 [5.0, 9.1] 7.1 [5.3, 9.1] 6.8 [5.0, 8.6] 7.1 [5.5, 9.5]
Total perioperative analgesic use (μg/kg) 8.5 [6.7, 10.2] 7.6 [6.0, 10.1] 7.7 [5.8, 10.2] 8.0 [6.2, 10.0] 7.8 [5.8, 9.6] 8.0 [6.3, 10.5]
VAS pain score at 3 h (mm) 27 [15, 47] 27 [15, 50] 27 [15, 50] 30 [15, 50] 27 [15, 50] 30 [16, 50]
VAS pain score at 24 h (mm) 25 [10, 38] 25 [10, 45] 22 [8, 40] 26 [11, 43] 23 [8, 40] 28 [14, 46]*
rs208293 rs1718136 rs7132846
GG GA + AA AA AG + GG CC CT + TT
Age (years) 27.5 ± 7.9 25.2 ± 7.4 26.2 ± 7.9 25.4 ± 6.9 25.7 ± 7.3 26.8 ± 8.8
Male/Female 41/70 84/160 95/152 30/78 104/170 21/60
PPLpre (s) 13 [9, 22] 15 [9, 24] 14 [9, 24] 15 [9, 21] 14 [9, 23] 14 [9, 23]
PPLpost (s) 27 [16, 51] 28 [16, 54] 29 [16, 56] 25 [15, 48] 28 [16, 53] 28 [16, 53]
Analgesic effect (PPLpost-PPLpre) (s) 10 [3, 34] 13 [5, 35] 13 [5, 36] 11 [4, 30] 12 [4, 35] 12 [4, 35]
24-h postoperative fentanyl use (μg/kg) 2.3 [1.1, 4.0] 2.3 [1.0, 4.3] 2.3 [1.1, 4.3] 2.0 [1.0, 4.1] 2.3 [1.1, 4.2] 2.3 [1.0, 4.2]
Perioperative fentanyl use (μg/kg) 6.8 [5.1, 9.0] 7.1 [5.3, 9.2] 7.0 [5.2, 9.2] 6.7 [5.2, 8.9] 6.9 [5.2, 9.1] 6.9 [5.2, 9.1]
Total perioperative analgesic use (μg/kg) 7.7 [5.9, 10.1] 8.0 [6.2, 10.1] 8.0 [6.1, 10.1] 7.7 [6.1, 9.9] 8.0 [6.1, 10.1] 8.0 [6.1, 10.1]
VAS pain score at 3 h (mm) 27 [16, 50] 27 [15, 49] 27 [15, 50] 26 [15, 49] 28 [15, 50] 27 [15, 50]
VAS pain score at 24 h (mm) 22 [10, 39] 26 [11, 45] 25 [10, 42] 25 [8, 42] 25 [10, 42] 25 [10, 42]
The data are expressed as numbers, mean ± SD (range), or median [interquartile range]. *p <0.05, compared with subjects not carrying minor allele.
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http://www.molecularpain.com/content/10/1/75perioperative fentanyl use, and total perioperative anal-
gesic use were not associated with haplotypes in the
P2RX7 gene. Although further validation is needed, the
analgesic/opioid requirements for postoperative pain
management might not be associated with genetic poly-
morphisms in the P2RX7 gene.Table 4 Estimated P2RX7 gene Tag SNP haplotypes and
their frequencies
Estimated haplotypes Frequency (SE)
1 ACGGAC 0.245 (0.016)
2 GCGGAC 0.229 (0.019)
3 GTAAAC 0.150 (0.014)
4 ATGAGC 0.103 (0.011)
5 GTAAAT 0.051 (0.010)
6 ACGGAT 0.048 (0.011)
7 ATAAGC 0.046 (0.009)
8 ACGAAC 0.041 (0.008)
9 ATAAAC 0.018 (0.014)
10 GTGGAC 0.016 (0.006)In the present study, subjects who carried homozy-
gous haplotype No.3 (GTAAAC) in the P2RX7 gene
exhibited higher cold pain sensitivity and lower anal-
gesic effects of fentanyl for acute cold pain in the cold
pressor test, but still unknown is whether this combin-
ation of SNPs alters gene function or expression, which
may be an important limitation of the present study.
Many SNPs have been identified in the P2RX7 gene,
and some of the SNPs in the P2RX7 gene have been
shown to cause changes in receptor function [22-24].
Although our present study did not focus on these re-
ported functional SNPs, some of them are located on
the present LD blocks. The rs208294 T/C SNP (Tyr155 to
His), which was described as the C489T SNP in previous
reports with non-Japanese subjects, is located in the LD3
region in the present study. This SNP showed high LD
(D’ =1.0) with the present 4th Tag SNP, rs208293 G/A
SNP. In the previous report, functional analyses in recom-
binant cells that expressed P2X7 receptors with the muta-
tion of the rs208294 SNP using [Ca2+]i influx and
ethidium uptake experiments revealed that the T > C
mutation in this position caused a loss of function of P2X7
Table 5 Associations between P2RX7 gene Tag SNP haplotypes and clinical data
PPLpre
Haplotypes Coefficient SE CI z-score p value
1 ACGGAC 13.245 6.576 (0.357, 26.134) 2.014 0.044
2 GCGGAC −0.23 4.252 (−8.563, 8.103) −0.05 0.957
3 GTAAAC −7.275 2.34 (−11.860, −2.689) −3.11 0.002
Analgesic effect (PPLpost-PPLpre)
Coefficient SE CI z-score p value
1 ACGGAC 19.452 9.34 (1.146, 37.759) 2.083 0.037
2 GCGGAC −2.966 6.87 (−16.431, 10.499) −0.43 0.666
3 GTAAAC −14.97 4.585 (−23.957, −5.983) −3.27 0.001
VAS pain score at 24 h
Coefficient SE CI z-score p value
1 ACGGAC 7.878 4.067 (−0.094, 15.849) 1.937 0.053
2 GCGGAC −10.799 3.523 (−17.705, −3.894) −3.07 0.002
3 GTAAAC 7.434 8.88 (−9.971, 24.839) 0.837 0.402
Haplotype-based associations were tested using linear regression analyses with a recessive model.
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http://www.molecularpain.com/content/10/1/75receptors [34]. Although the rs208293 G/A SNP alone
did not show any association with cold pain sensitivity
and the analgesic effects of fentanyl, the rs208294 T/C
SNP might be one of the mutations in LD1-3 that
caused the present results. Interestingly, P2X7 receptors
have been reported to contain several alternative spli-
cing variants (P2X7a-k), some of which presented
altered function [35-38]. Because the splicing difference
in more than half of these isoforms occurs from the
LD1 to LD3 regions (from exon 1 to exon 5) in the
P2RX7 gene, polymorphisms in these regions might
affect this splicing mechanism and induce a functional
change in neuronal transmission via P2X7 receptors.
Further studies that focus on gene polymorphisms from
LD1 to LD3 in the P2RX7 gene may reveal the
functional mechanisms that affect pain sensitivity and
clinical efficacy of opioids. A recent report showed
a genetic association between the hypofunctional
rs7958311 G/A SNP (Arg270 to His) and lower pain in-
tensity in two cohort studies of human patients with
chronic pain [24]. The rs7958311 G/A SNP is located
in the gap between the present LD4 and LD5 regions.
Including this SNP, some other nonsynonymous SNPs
(e.g., rs3751143 A/C SNP [Glu496 to Ala] [22]) are lo-
cated in the gap among the present LD regions and
were not evaluated in the present study. Further asso-
ciation analyses of these SNPs in the P2RX7 gene may
be necessary to reveal the role and mechanisms of
P2X7 receptors in naive pain sensitivity and the efficacy
of analgesics.
The potential of P2X7 receptors as a therapeutic target
in the management of neuropathic pain and inflammationhas been the subject of intensive recent investigations
[2,3,39], but the involvement of P2X7 receptors in the
modulation of naive pain sensitivity and efficacy of analge-
sics is still unclear. P2X7 receptors are expressed predom-
inantly on immune cells, and are speculated to contribute
to the hyperexcitability of nociceptive neurons through
the release of both interleukin-1β (IL-1β) and tumor ne-
crosis factor α (TNF-α) [40-42]. These cytokines are well
known to play important roles in the generation and
maintenance of pain, and especially in chronic pain states
[39,42]. P2X7 receptors are also known to act not only as
cation channels following brief activation by extracellular
ATP but also as large nonselective pores following pro-
longed or repeated activation. Sorge et al. reported that
mice that carried a mutation in the P2RX7 gene that
causes impaired pore formation showed less hypersensitiv-
ity in neuropathic and inflammatory pain states [24].
These previous data might indicate that the pore forma-
tion of P2X7 receptors closely affects chronic pain states
[43]. In the present study, haplotype No.2 (GCGGAC) and
the rs1718125 SNP in the P2RX7 gene showed associa-
tions with VAS scores at 24 h but not with VAS scores at
3 h or the analgesic effects of fentanyl in the cold pressor
test. Immediate pain transmission in the cold pressor test
and the acute phase of postoperative pain (reflected by
VAS score at 3 h) might have different pain-modulated
mechanisms from subacute postoperative pain (VAS score
at 24 h), and the latter might be affected by the pore
formation of P2X7 receptors. Further validation of the
relationship between these P2RX7 gene polymorphisms
and time-dependent changes in postoperative pain
states is needed to clarify this issue.
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http://www.molecularpain.com/content/10/1/75The present study revealed that PPLpre and PPLpost-
PPLpre in the cold pressor test were associated with
haplotypes of the SNPs (haplotype No.1 and No.3) in the
P2RX7 gene, suggesting that P2X7 receptors are involved
in cold pain transmission and the analgesic effects of
opioids for cold pain stimuli under naive conditions.
However, these haplotypes showed no significant asso-
ciation with clinical pain conditions (VAS scores) or fen-
tanyl requirements. The pain stimulus in the cold
pressor test may be mediated by the activation of transi-
ent receptor potential ankyrin 1 (TRPA1) channels in
primary sensory neurons [44]. Postoperative pain may be
mediated mainly by the activation of transient receptor
potential vanilloid 1 (TRPV1) channels subsequent to
incision and inflammation and not by the activation of
TRPA1 channels [45]. P2X7 receptors are well known
to act as ATP-gated Ca2+-permeable cation channels.
Furthermore, the function of TRP channels might be
regulated by external Ca2+ [46]. Thus, together with
our present results, TRPA1 channels may be affected
by the channel function of P2X7 receptors, and TRPV1
channels may be affected by the pore formation of
P2X7 receptors. Although further investigation and
validation are needed to confirm this hypothesis, P2X7
receptors are suggested to play differential roles in pain
transmission, depending on the type of pain stimulus.
Furthermore, the mechanisms of P2X7 receptor-induced
alterations in the analgesic effects of opioids are still un-
clear. Only a few reports have shown that the blockade
of P2X7 receptors with specific antagonists or targeting
small interfering RNA (siRNA) enhanced the analgesic
effects of morphine in chronic morphine-treated (i.e.,
morphine-tolerant) rats, although these effects were not
evident in naive rats [47,48]. Thus, neuronal modulation
via P2X7 receptors may affect the analgesic effects of
opioids, but these modulatory effects may depend on
the type of pain stimulus or pain expression (i.e., acute
or chronic).
Conclusions
In Japanese subjects, naive cold pain sensitivity and
the analgesic effect of fentanyl were related to an SNP
and haplotypes in the P2RX7 gene. The rs1718125
G > A SNP tended to be associated with higher VAS
scores at 24 h after mandibular sagittal split ramus
osteotomy. Furthermore, subjects with homozygous
haplotype No.3 (GTAAAC) exhibited higher cold pain
sensitivity and lower analgesic effects of fentanyl for
acute cold pain in the cold pressor test. The combin-
ation of polymorphisms from the 5′-flanking region to
exon 5 in the P2RX7 gene could recessively affect cold
pain sensitivity and the analgesic effects of opioids for
acute cold pain. Subjects with homozygous haplotype
No.2 (GCGGAC) had lower VAS scores at 24 h aftersurgery. Although further validation is needed, our
data may provide valuable information about the role of
P2X7 receptors in pain pathways and pain treatment.
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